The significance of major and stable molecular responses in chronic myeloid leukemia in the tyrosine kinase inhibitor era

Revista Brasileira de Hematologia e Hemoterapia

Ilana Zalcberg Renault²  Vanesa Scholl²  Rocio Hassan²  Paola Capelleti²  Marcos De Lima¹  Jorge Cortes¹ 

[1] ,Instituto Nacional de Câncer Bone Marrow Transplantation Center Molecular Biology LaboratoryRio de Janeiro RJ ,Brazil

关键词: Leukemia;    myelogenous;    chronic;    BCR-ABL positive;    Cytogenetic;    Monitoring;    Mutation;    Polymerase chain reaction;   

DOI  :  10.5581/1516-8484.20110122

来源: SciELO

【 摘 要 】

Tyrosine kinase inhibitors have changed the management and outcomes of chronic myeloid leukemia patients. Quantitative polymerase chain reaction is used to monitor molecular responses to tyrosine kinase inhibitors. Molecular monitoring represents the most sensitive tool to judge chronic myeloid leukemia disease course and allows early detection of relapse. Evidence of achieving molecular response is important for several reasons: 1. early molecular response is associated with major molecular response rates at 18-24 months; 2. patients achieving major molecular response are less likely to lose their complete cytogenetic response; 3. a durable, stable major molecular response is associated with increased progression-free survival. However, standardization of molecular techniques is still challenging.

【 授权许可】

CC BY-NC-ND   
 All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License